Pharmaceuticals, Biotechnology and Life Sciences
AstraZeneca on Monday reported closing two different agreements for certain commercial rights for its drugs, in Europe and worldwide.
Bayer said on Friday it would cut its full-year earnings forecast due to high inventories at crop protection distributors in Brazil and a weaker-than-expected consumer health business.
Roche has bought Vienna-based diabetes management platform mySugr for an undisclosed price, the Swiss drugmaker said on Friday, joining a growing crowd of companies expanding into app-based digital health services.
Oxford BioDynamics, focused on the epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, has appointed new chief financial officer who is expected to join the company by the mid of September 2017.
ImmuPharma said Friday that 200 patients were recruited and dosed in its Phase III trial of Lupus drug Lupuzor. Furthermore, all 200 patients have passed the 3 months stage, with over 90% of patients (184) have passed 6 months.
N4 Pharma provided latest research results for its Nuvec nanoparticles which it is developing as a delivery system for DNA and mRNA vaccines and therapeutics.
About a quarter of countries in sub-Saharan Africa receive little funding for research into malaria despite having high death rates, according to a study on Thursday that highlighted the unequal spread of resources to tackle the disease.
Novartis and Merck have both surprised experts in the past week by finding new ways to tackle heart disease, although the jury remains out as to whether this scientific success will translate into blockbuster sales.
Drugstore chain Walgreens Boots Alliance Inc
AstraZeneca and Chi-Med said on Thursday they kicked off the third phase of clinical testing of their cancer drug.